These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21062637)

  • 1. The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects.
    Hallak JE; Dursun SM; Bosi DC; de Macedo LR; Machado-de-Sousa JP; Abrão J; Crippa JA; McGuire P; Krystal JH; Baker GB; Zuardi AW
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):198-202. PubMed ID: 21062637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.
    Gouzoulis-Mayfrank E; Heekeren K; Neukirch A; Stoll M; Stock C; Obradovic M; Kovar KA
    Pharmacopsychiatry; 2005 Nov; 38(6):301-11. PubMed ID: 16342002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists.
    Krupitsky EM; Burakov AM; Romanova TN; Grinenko NI; Grinenko AY; Fletcher J; Petrakis IL; Krystal JH
    Neuropsychopharmacology; 2001 Dec; 25(6):936-47. PubMed ID: 11750186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude.
    Oranje B; Gispen-de Wied CC; Westenberg HG; Kemner C; Verbaten MN; Kahn RS
    Int J Neuropsychopharmacol; 2009 Jul; 12(6):823-32. PubMed ID: 19154656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.
    Anand A; Charney DS; Oren DA; Berman RM; Hu XS; Cappiello A; Krystal JH
    Arch Gen Psychiatry; 2000 Mar; 57(3):270-6. PubMed ID: 10711913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
    Krystal JH; Abi-Saab W; Perry E; D'Souza DC; Liu N; Gueorguieva R; McDougall L; Hunsberger T; Belger A; Levine L; Breier A
    Psychopharmacology (Berl); 2005 Apr; 179(1):303-9. PubMed ID: 15309376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The acute effects of NMDA antagonism: from the rodent to the human brain.
    Gunduz-Bruce H
    Brain Res Rev; 2009 May; 60(2):279-86. PubMed ID: 18703087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicotine and smoker status moderate brain electric and mood activation induced by ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist.
    Knott V; McIntosh J; Millar A; Fisher D; Villeneuve C; Ilivitsky V; Horn E
    Pharmacol Biochem Behav; 2006 Sep; 85(1):228-42. PubMed ID: 17023037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamate-induced temporomandibular joint pain in healthy individuals is partially mediated by peripheral NMDA receptors.
    Alstergren P; Ernberg M; Nilsson M; Hajati AK; Sessle BJ; Kopp S
    J Orofac Pain; 2010; 24(2):172-80. PubMed ID: 20401355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors.
    Bubeníková-Valesová V; Horácek J; Vrajová M; Höschl C
    Neurosci Biobehav Rev; 2008 Jul; 32(5):1014-23. PubMed ID: 18471877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamatergic aspects of schizophrenia.
    Tamminga C
    Br J Psychiatry Suppl; 1999; (37):12-5. PubMed ID: 10211134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The NMDA antagonist model for schizophrenia: promise and pitfalls.
    Abi-Saab WM; D'Souza DC; Moghaddam B; Krystal JH
    Pharmacopsychiatry; 1998 Jul; 31 Suppl 2():104-9. PubMed ID: 9754841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only.
    Fride E; Feigin C; Ponde DE; Breuer A; Hanus L; Arshavsky N; Mechoulam R
    Eur J Pharmacol; 2004 Dec; 506(2):179-88. PubMed ID: 15588739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways.
    Chizh BA
    J Psychopharmacol; 2007 May; 21(3):259-71. PubMed ID: 17591654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the discriminative stimulus effects of N-methyl- D-aspartate ligands under different ethanol training conditions in the cynomolgus monkey ( Macaca fascicularis).
    Vivian JA; Waters CA; Szeliga KT; Jordan K; Grant KA
    Psychopharmacology (Berl); 2002 Jul; 162(3):273-81. PubMed ID: 12122485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMDA receptor antagonists and pain: ketamine.
    Muir WW
    Vet Clin North Am Equine Pract; 2010 Dec; 26(3):565-78. PubMed ID: 21056300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.
    Malhotra AK; Pinals DA; Weingartner H; Sirocco K; Missar CD; Pickar D; Breier A
    Neuropsychopharmacology; 1996 May; 14(5):301-7. PubMed ID: 8703299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
    Krystal JH; Karper LP; Seibyl JP; Freeman GK; Delaney R; Bremner JD; Heninger GR; Bowers MB; Charney DS
    Arch Gen Psychiatry; 1994 Mar; 51(3):199-214. PubMed ID: 8122957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.
    Sagredo O; Ramos JA; Decio A; Mechoulam R; Fernández-Ruiz J
    Eur J Neurosci; 2007 Aug; 26(4):843-51. PubMed ID: 17672854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.